Levetiracetam for Persons at Risk for Alzheimer's Disease — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Levetiracetam for Persons at Risk for Alzheimer's Disease — Stella

Home/Hippocampal Hyperactivation/

View on ClinicalTrials.gov

Recruiting

Back to Hippocampal Hyperactivation trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

Canada

Sunnybrook Health Sciences Centre, Toronto, Ontario

Toronto Western Hospital, Toronto, Ontario

Key details

Phase

Safety & dosing

Sponsor

Sunnybrook Health Sciences Centre

Collaborators

University Health Network, Toronto, Weston Brain Institute

Enrollment target

~40 participants

Started

October 2025

Primary completion

January 2027

Age range

55 Years – 85 Years

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.